DiaGenic
From Wikipedia, the free encyclopedia
| DiaGenic ASA | |
|---|---|
| Type | Public (OSE: DIAG) |
| Founded | 1998 |
| Headquarters | Oslo, Norway |
| Area served | Global |
| Key people | Erik Christensen (CEO) Ingrid Alfheim (Chairman) |
| Industry | Pharmeceuticals |
| Services | Diagnostic tests |
| Revenue | NOK 60,000 (2006) |
| Operating income | NOK -23.3 million (2006) |
| Profit | NOK -22.7 million (2006) |
| Website | diagenic.com |
DiaGenic (OSE: DIAG) is a Norwegian pharmaceutical company. It aims to develop tests for early diagnosis of diseases where only early intervention is necessary for successful treatment. It has patented methods to indentify disease-specific gene signatures from sample material like blood. The company is based in Oslo and listed on the Oslo Stock Exchange.
Large amounts of the research is funded by the Research Council of Norway.
